Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | TLR4 | O00206 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14159804 | 0.94 | POLB (0.35) | CA1CA2CA4KMT2APOLB | |
| SCHEMBL9409642 | 0.94 | POLB (0.35) | CA1CA2CA4KMT2APOLB | |
| SCHEMBL27053573 | 0.85 | POLB (0.37) | KMT2APOLBAPEX1RECQLTDP1 | |
| SCHEMBL2038990 | 0.80 | ALDH1A1 (0.39) | KMT2APOLBHSD11B1RECQLTDP1 | |
| SCHEMBL14284261 | 0.80 | ALDH1A1 (0.39) | KMT2APOLBHSD11B1RECQLTDP1 | |
| SCHEMBL30879564 | 0.80 | ALDH1A1 (0.39) | KMT2APOLBHSD11B1RECQLTDP1 | |
| SCHEMBL30288152 | 0.80 | ALDH1A1 (0.39) | KMT2APOLBHSD11B1RECQLTDP1 | |
| SCHEMBL30288169 | 0.80 | ALDH1A1 (0.39) | KMT2APOLBHSD11B1RECQLTDP1 | |
| SCHEMBL4951220 | 0.71 | ALDH1A1 (0.42) | KMT2APOLBRECQLTDP1L3MBTL1 | |
| SCHEMBL22263673 | 0.69 | HSD11B1 (0.41) | POLBHSD11B1HSD11B2APEX1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8278311-B2 | Substituted pyrimidine derivatives | ABBOTT LABORATORIES (US) | 2012-10-02 | — | — | US | disclosed |
| US-20090270364-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES | ABBOTT LABORATORIES (US) | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270364-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES | DPYD, TYMP, TYMS | CA1 4792/4885CA2 4838/4885CA4 4682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.